These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19273686)

  • 1. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
    Louie A; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D; van Ogtrop ML; Peng J; Craig WA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.
    Keel RA; Tessier PR; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.
    Guo Y; Ramos RI; Cho JS; Donegan NP; Cheung AL; Miller LS
    Antimicrob Agents Chemother; 2013 Feb; 57(2):855-63. PubMed ID: 23208713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
    Jacqueline C; Batard E; Perez L; Boutoille D; Hamel A; Caillon J; Kergueris MF; Potel G; Bugnon D
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3706-11. PubMed ID: 12435665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
    Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
    Banevicius MA; Kaplan N; Hafkin B; Nicolau DP
    J Chemother; 2013 Feb; 25(1):26-31. PubMed ID: 23433441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.
    Fernandez J; Hilliard JJ; Morrow BJ; Melton JL; Flamm RK; Barron AM; Lynch AS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5522-8. PubMed ID: 21911568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.
    LaPlante KL; Leonard SN; Andes DR; Craig WA; Rybak MJ
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2156-62. PubMed ID: 18411321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Ribes S; Pachón-Ibáñez ME; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1361-7. PubMed ID: 20680368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.
    Yanagihara K; Kaneko Y; Sawai T; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3288-91. PubMed ID: 12234863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.
    Tessier PR; Keel RA; Hagihara M; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 May; 56(5):2342-6. PubMed ID: 22354302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?
    Kalil AC; Puumala S; Stoner J
    Antimicrob Agents Chemother; 2006 May; 50(5):1910; author reply 1910-1. PubMed ID: 16641477
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit.
    Smith RL; Evans HL; Chong TW; McElearney ST; Hedrick TL; Swenson BR; Scheld WM; Pruett TL; Sawyer RG
    Surg Infect (Larchmt); 2008 Aug; 9(4):423-31. PubMed ID: 18759679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo antibacterial activity of MRX-I, a new oxazolidinone.
    Li CR; Zhai QQ; Wang XK; Hu XX; Li GQ; Zhang WX; Pang J; Lu X; Yuan H; Gordeev MF; Chen LT; Yang XY; You XF
    Antimicrob Agents Chemother; 2014; 58(4):2418-21. PubMed ID: 24395231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.